Low-density Lipoprotein Receptor Activities, Lipids, Apolipoprotein, and Clinical Course of Patients with Steroid-resistant Nephrotic Syndrome Treated with Low-density Lipoprotein Apheresis: A Case Series

Intern Med. 2024 Feb 1;63(3):433-438. doi: 10.2169/internalmedicine.1922-23. Epub 2023 May 31.

Abstract

We herein report three cases of steroid-resistant nephrotic syndrome successfully treated with low-density lipoprotein apheresis (LDL-A). All patients were treated with a combination of steroids, cyclosporine, and LDL-A. In all cases, the serum concentrations of LDL, total and high-density lipoprotein cholesterol, and triglycerides were significantly lowered following LDL-A administration. Furthermore, the estimated LDL receptor activity increased, while both serum LDL and total cholesterol levels decreased, suggesting that LDL-A increases LDL receptor activity by driving changes in serum cholesterol concentration. This case series suggests that LDL-A increases LDL receptor activity, which may improve the intracellular uptake of cyclosporine.

Keywords: LDL receptor activity; focal segmental glomerulosclerosis; hyperlipidemia; low-density lipoprotein apheresis; nephrotic syndrome.

MeSH terms

  • Apolipoproteins / therapeutic use
  • Blood Component Removal*
  • Cholesterol
  • Cyclosporine / therapeutic use
  • Disease Progression
  • Glomerulosclerosis, Focal Segmental*
  • Humans
  • Lipoproteins, LDL / therapeutic use
  • Nephrotic Syndrome* / drug therapy
  • Receptors, LDL

Substances

  • Lipoproteins, LDL
  • Cyclosporine
  • Apolipoproteins
  • Receptors, LDL
  • Cholesterol